| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/26/2012 | US20120020978 Antibodies against fatty acid synthase |
| 01/26/2012 | US20120020977 Pancreatic cancer genes |
| 01/26/2012 | US20120020976 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020975 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
| 01/26/2012 | US20120020974 Optimizing erythropoietin therapy |
| 01/26/2012 | US20120020973 Chimeric ospa genes, proteins, and methods of use thereof |
| 01/26/2012 | US20120020972 Antibodies relating to pivka-ii and uses thereof |
| 01/26/2012 | US20120020971 Antibodies useful in passive influenza immunization |
| 01/26/2012 | US20120020970 Methods of evaluating patients |
| 01/26/2012 | US20120020969 Compositions And Methods For Inhibiting Viral Adhesion |
| 01/26/2012 | US20120020968 Chimeric DRG11-Responsive (DRAGON) Polypeptides |
| 01/26/2012 | US20120020967 VEGF antibodies comprising modular recognition domains |
| 01/26/2012 | US20120020966 Multispecific antibody targeting and multivalency through modular recognition domains |
| 01/26/2012 | US20120020965 Molecules that bind CD180, compositions and methods of use |
| 01/26/2012 | US20120020964 Antibodies for Norovirus |
| 01/26/2012 | US20120020963 Anti-inteferon alpha monoclonal antibodies and methods for use |
| 01/26/2012 | US20120020962 Method of depleting regulatory t cell |
| 01/26/2012 | US20120020961 Methods and compositions for liver cancer therapy |
| 01/26/2012 | US20120020960 Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
| 01/26/2012 | US20120020959 Use of the sparc microenvironment signature in the treatment of cancer |
| 01/26/2012 | US20120020958 Fibcd1 for the prevention and treatment of diseases |
| 01/26/2012 | US20120020957 Dengue virus neutralizing antibodies and use thereof |
| 01/26/2012 | US20120020956 Activation of sodium potassium atpase |
| 01/26/2012 | US20120020955 Detection of Neurological Disorders With Immune Reactions |
| 01/26/2012 | US20120020954 Methods of predicting clinical course and treating multiple sclerosis |
| 01/26/2012 | US20120020953 Diagnosis and treatment of cancer |
| 01/26/2012 | US20120020951 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects |
| 01/26/2012 | US20120020950 Antibacterial compounds |
| 01/26/2012 | US20120020949 MHC-LESS cells |
| 01/26/2012 | US20120020922 Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
| 01/26/2012 | US20120020916 Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases |
| 01/26/2012 | US20120020915 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System |
| 01/26/2012 | US20120020913 Methods for pancreatic tissue regeneration |
| 01/26/2012 | US20120020912 Prostate cancer vaccine |
| 01/26/2012 | US20120020890 Staphylococcus aureus proteins and nucleic acids |
| 01/26/2012 | US20120020888 Biomarker |
| 01/26/2012 | US20120020880 Cytotoxicity Mediation of Cells Evidencing Surface Expression of CD44 |
| 01/26/2012 | US20120020879 Process, composition and method for anion deposition into ferritin for therapeutic and other use |
| 01/26/2012 | US20120020878 Fusogenic properties of saposin c and related proteins and peptides for application to transmembrane drug delivery systems |
| 01/26/2012 | CA2806362A1 Administration of rifalazil to immunocompromised patients |
| 01/26/2012 | CA2806250A1 Cross-protective pathogen protection, methods and compositions thereof |
| 01/26/2012 | CA2806076A1 Anti-tumor antigen antibodies and methods of use |
| 01/26/2012 | CA2805994A1 Anti-cd19 antibody having adcc and cdc functions and improved glycosylation profile |
| 01/26/2012 | CA2805985A1 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
| 01/26/2012 | CA2805978A1 Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition |
| 01/26/2012 | CA2805963A1 A method of treating attention deficit hyperactivity disorder |
| 01/26/2012 | CA2805961A1 A combination pharmaceutical composition and methods of treating diabetes and metabolic disorders |
| 01/26/2012 | CA2805943A1 A method of treating alzheimer's disease |
| 01/26/2012 | CA2805753A1 Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy |
| 01/26/2012 | CA2805741A1 Influenza vaccine |
| 01/26/2012 | CA2805653A1 Anti-il-23 heterodimer specific antibodies |
| 01/26/2012 | CA2804998A1 Peptide compounds for regulating the complement system |
| 01/26/2012 | CA2804890A1 Parapoxvirus vectors |
| 01/26/2012 | CA2768866A1 High yield yellow fever virus strain with increased propagation in cells |
| 01/25/2012 | EP2410055A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/25/2012 | EP2409992A1 A human anti-tumor necrosis factor alpha monoclonal antibody and use thereof |
| 01/25/2012 | EP2409991A1 Antibody constant region variant |
| 01/25/2012 | EP2409990A1 Antibody constant region variant |
| 01/25/2012 | EP2409987A1 Ribosomal P protein complex from Plasmodium falciparum as antigen against malaria |
| 01/25/2012 | EP2408934A1 Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof |
| 01/25/2012 | EP2408926A2 Production of recombinant proteins in ciliates and uses thereof |
| 01/25/2012 | EP2408913A1 Neil3 peptides and vaccines including the same |
| 01/25/2012 | EP2408820A1 Humanised antibodies with anti-tumour activity |
| 01/25/2012 | EP2408819A2 High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof |
| 01/25/2012 | EP2408477A1 Replication-defective flavivirus vaccine vectors against respiratory syncytial virus |
| 01/25/2012 | EP2408476A2 Human immunodeficiency virus (hiv) -neutralizing antibodies |
| 01/25/2012 | EP2408475A1 Flagellin fusion proteins and use thereof to induce immune responses against pseudomonas aeruginosa |
| 01/25/2012 | EP2408474A2 Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| 01/25/2012 | EP2408473A1 Vaccination methods |
| 01/25/2012 | EP2408467A2 A method and composition using a dual specificity protein tyrosine phosphatase as an antimalarial drug target |
| 01/25/2012 | EP2408466A2 Agents and methods for tissue repair and regeneration |
| 01/25/2012 | EP2408465A2 Methods and compositions for the detection of cancer |
| 01/25/2012 | EP2408455A2 Inhibitors of cathepsin s for prevention or treatment of obesity-associated disorders |
| 01/25/2012 | EP2408430A1 In situ constituting a vaccine for administration to a predetermined herd of animals |
| 01/25/2012 | EP2167664B1 Hybrid operon for expression of colonization factor (cf) antigens of enterotoxigenic escherichia coli |
| 01/25/2012 | EP2069791B1 Cellular receptor for antiproliferative factor |
| 01/25/2012 | EP1959992B1 Immunogenic composition comprising an adjuvant |
| 01/25/2012 | EP1613659B1 New monoclonal antibody capable of binding integrin alpha 10 beta 1 |
| 01/25/2012 | EP1545613B9 Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 01/25/2012 | EP1532167B1 Molecular antigen arrays using a virus like particle derived from the ap205 coat protein |
| 01/25/2012 | EP1434597B1 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 01/25/2012 | EP1412379B1 Vaccine |
| 01/25/2012 | EP1361794B1 Pro-apoptotic bacterial vaccines to enhance cellular immune responses |
| 01/25/2012 | EP1355918B9 Recombinant protective protein from $i(streptococcus pneumoniae) |
| 01/25/2012 | EP1351707B9 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 01/25/2012 | EP1068293B1 Vaccination modalities |
| 01/25/2012 | EP1019437B1 Method for the covalent attachment of polysaccharides to protein molecules |
| 01/25/2012 | EP0791055B1 Method for producing biologicals in protein-free culture |
| 01/25/2012 | CN1919341B Application of hepatitis B surface antigen-antibody complexes in preparing prophylaxis product with no response or low response to hepatitis B vaccine |
| 01/25/2012 | CN1894026B Cryogranulation and storage method for active pharmaceutical agents |
| 01/25/2012 | CN1374870B Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody |
| 01/25/2012 | CN102333877A Methods and compositions for use of a coccidiosis vaccine |
| 01/25/2012 | CN102333876A Pcv 2-based methods and compositions for the treatment of pigs |
| 01/25/2012 | CN102333867A C1orf59 peptides and vaccines including the same |
| 01/25/2012 | CN102333791A Generation, expression and characterization of the humanized k33n monoclonal antibody |
| 01/25/2012 | CN102333789A Anti-herpes simplex virus antibodies and methods of use thereof |
| 01/25/2012 | CN102333544A Methods of treating vascular lesions |
| 01/25/2012 | CN102333543A Cell adhesion inhibitor and use thereof |
| 01/25/2012 | CN102333542A Pcsk9拮抗剂 Pcsk9 antagonist |
| 01/25/2012 | CN102333541A Immunogenic composition |